Enzon Stock Hits New 52-Week Low (ENZN)

NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) hit a new 52-week low Friday as it is currently trading at $9.97, below its previous 52-week low of $10 with 901,487 shares traded as of four p.m. ET. Average volume has been 434,900 shares over the past 30 days.

Enzon has a market cap of $538.9 million and is part of the health care sector and drugs industry. Shares are down 16.2% year to date as of the close of trading on Thursday.

Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for patients with cancer primarily in the United States and Europe. Its drug development program utilizes Customized Linker technology and the Locked Nucleic Acid technology.
  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Enzon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Global Stocks Retreat as U.S.-China Trade War Intensifies

Global Stocks Retreat as U.S.-China Trade War Intensifies

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street